6 results on '"Mohyeldin, Ahmed"'
Search Results
2. Pyruvate Dehydrogenase Complex Activity Controls Metabolic and Malignant Phenotype in Cancer Cells.
- Author
-
McFate, Thomas, Mohyeldin, Ahmed, Huasheng Lu, Thakar, Jay, Henriques, Jeremy, Halim, Nader D., Hong Wu, Schell, Michael J., Tsz Mon Tsang, Teahan, Orla, Shaoyu Zhou, Califano, Joseph A., Nam Ho Jeoung, Harris, Robert A., and Verma, Ajay
- Subjects
- *
GENOTYPE-environment interaction , *DEHYDROGENASES , *BIOCHEMISTRY , *TRANSCRIPTION factors , *SQUAMOUS cell carcinoma , *PHOTOSYNTHETIC oxygen evolution - Abstract
High lactate generation and low glucose oxidation, despite normal oxygen conditions, are commonly seen in cancer cells and tumors. Historically known as the Warburg effect, this altered metabolic phenotype has long been correlated with malignant progression and poor clinical outcome. However, the mechanistic relationship between altered glucose metabolism and malignancy remains poorly understood. Here we show that inhibition of pyruvate dehydrogenase complex (PDC) activity contributes to the Warburg metabolic and malignant phenotype in human head and neck squamous cell carcinoma. PDC inhibition occurs via enhanced expression of pyruvate dehydrogenase kinase-1 (PDK-1), which results in inhibitory phosphorylation of the pyruvate dehydrogenase a (PDHα) subunit. We also demonstrate that PDC inhibition in cancer cells is associated with normoxic stabilization of the malignancy-promoting transcription factor hypoxia-inducible factor-1α (HIF-1α) by glycolytic metabolites. Knockdown of PDK-1 via short hairpin RNA lowers PDHα phosphorylation, restores PDC activity, reverts the Warburg metabolic phenotype, decreases normoxic HIF-1α expression, lowers hypoxic cell survival, decreases invasiveness, and inhibits tumor growth. PDK-1 is an HIF-1-regulated gene, and these data suggest that the buildup of glycolytic metabolites, resulting from high PDK-l expression, may in turn promote HIF-1 activation, thus sustaining a feed-forward loop for malignant progression. In addition to providing anabolic support for cancer cells, altered fuel metabolism thus supports a malignant phenotype. Correction of metabolic abnormalities offers unique opportunities for cancer treatment and may potentially synergize with other cancer therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
3. Erythropoietin Signaling Promotes Invasiveness of Human Head and Neck Squamous Cell Carcinoma.
- Author
-
Mohyeldin, Ahmed, Huasheng Lu, Dalgard, Clifton, Lai, Stephen Y., Cohen, Noam, Acs, Geza, and Verma, Ajay
- Subjects
- *
ERYTHROPOIETIN , *COLONY-stimulating factors (Physiology) , *ANEMIA , *CANCER patients , *HEMATOPOIETIC growth factors - Abstract
Erythropoietin (Epo) is used for managing anemia in cancer patients. However, recent studies have raised concerns for this practice. We investigated the expression and function of Epo and the erythropoietin receptor (EpoR) in tumor biopsies and cell lines from human head and neck cancer. Epo responsiveness of the cell lines was assessed by Epoetin-α-induced tyrosine phosphorylation of the Janus kinase 2 (JAK2) protein kinase. Transmigration assays across Matrigel-coated filters were used to examine the effects of Epoetin-α on cell invasiveness. In 32 biopsies, we observed a significant association between disease progression and expression of Epo and its receptor, EpoR. Expression was highest in malignant cells, particularly within hypoxic and infiltrating tumor regions. Although both Epo and EpoR were expressed in human head and neck carcinoma cell lines, only EpoR was upregulated by hypoxia. Epoetin-α treatment induced prominent JAK2 phosphorylation and enhanced cell invasion. Inhibition of JAK2 phosphorylation reduced both basal and Epo-induced invasiveness. Our findings support a role for autocrine or paracrine Epo signaling in the malignant progression and local invasiveness of head and neck cancer. This mechanism may also be activated by recombinant Epo therapy and could potentially produce detrimental effects in rhEpo-treated cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
4. Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1.
- Author
-
Huasheng Lu, Dalgard, Clifton L., Mohyeldin, Ahmed, McFate, Thomas, Tait, A. Sasha, and Verma, Ajay
- Subjects
- *
PROLINE hydroxylase , *OXIDOREDUCTASES , *CELL metabolism , *CELL respiration , *CELLULAR control mechanisms , *BASAL metabolism , *BLOOD-vessel development , *PROTEOMICS , *TRANSCRIPTION factors - Abstract
Continuous hydroxylation of the HIF-1 transcription factor a subunit by oxygen and 2-oxoglutarate-dependent dioxygenases promotes decay of this protein and thus prevents the transcriptional activation of many genes involved in energy metabolism, angiogenesis, cell survival, and matrix modification. Hypoxia blocks HIF-1α hydroxylation and thus activates HIF-1α-mediated gene expression. Several nonhypoxic stimuli can also activate HIF-1, although the mechanisms involved are not well known. Here we show that the glucose metabolites pyruvate and oxaloacetate inactivate HIF-1α decay in a manner selectively reversible by ascorbate, cysteine, histidine, and ferrous iron but not by 2-oxoglutarate or oxygen. Pyruvate and oxaloacetate bind to the 2-oxoglutarate site of HIF-1α prolyl hydroxylases, but their effects on HIF-1 are not mimicked by other Krebs cycle intermediates, including succinate and fumarate. We show that inactivation of HIF-1 hydroxylation by glucose-derived 2-oxoacids underlies the prominent basal HIF-1 activity commonly seen in many highly glycolytic cancer cells. Since HIF-1 itself promotes glycolytic metabolism, enhancement of HIF-1 by glucose metabolites may constitute a novel feed-forward signaling mechanism involved in malignant progression. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
5. Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner.
- Author
-
Kim, Sung-Hak, Ezhilarasan, Ravesanker, Phillips, Emma, Gallego-Perez, Daniel, Sparks, Amanda, Taylor, David, Ladner, Katherine, Furuta, Takuya, Sabit, Hemragul, Chhipa, Rishi, Cho, Ju Hwan, Mohyeldin, Ahmed, Beck, Samuel, Kurozumi, Kazuhiko, Kuroiwa, Toshihiko, Iwata, Ryoichi, Asai, Akio, Kim, Jonghwan, Sulman, Erik P., and Cheng, Shi-Yuan
- Subjects
- *
SERINE/THREONINE kinases , *MESENCHYMAL stem cells , *GLIOMAS , *STEM cells , *NF-kappa B - Abstract
Summary Activation of nuclear factor κB (NF-κB) induces mesenchymal (MES) transdifferentiation and radioresistance in glioma stem cells (GSCs), but molecular mechanisms for NF-κB activation in GSCs are currently unknown. Here, we report that mixed lineage kinase 4 (MLK4) is overexpressed in MES but not proneural (PN) GSCs. Silencing MLK4 suppresses self-renewal, motility, tumorigenesis, and radioresistance of MES GSCs via a loss of the MES signature. MLK4 binds and phosphorylates the NF-κB regulator IKKα, leading to activation of NF-κB signaling in GSCs. MLK4 expression is inversely correlated with patient prognosis in MES, but not PN high-grade gliomas. Collectively, our results uncover MLK4 as an upstream regulator of NF-κB signaling and a potential molecular target for the MES subtype of glioblastomas. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
6. Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors.
- Author
-
Pavlyukov, Marat S., Yu, Hai, Bastola, Soniya, Minata, Mutsuko, Shender, Victoria O., Lee, Yeri, Zhang, Suojun, Wang, Jia, Komarova, Svetlana, Wang, Jun, Yamaguchi, Shinobu, Alsheikh, Heba Allah, Shi, Junfeng, Chen, Dongquan, Mohyeldin, Ahmed, Kim, Sung-Hak, Shin, Yong Jae, Anufrieva, Ksenia, Evtushenko, Evgeniy G., and Antipova, Nadezhda V.
- Subjects
- *
APOPTOTIC bodies , *VESICLES (Cytology) , *GLIOBLASTOMA multiforme , *RNA splicing , *CELL proliferation , *SPLICEOSOMES - Abstract
Summary Aggressive cancers such as glioblastoma (GBM) contain intermingled apoptotic cells adjacent to proliferating tumor cells. Nonetheless, intercellular signaling between apoptotic and surviving cancer cells remain elusive. In this study, we demonstrate that apoptotic GBM cells paradoxically promote proliferation and therapy resistance of surviving tumor cells by secreting apoptotic extracellular vesicles (apoEVs) enriched with various components of spliceosomes. apoEVs alter RNA splicing in recipient cells, thereby promoting their therapy resistance and aggressive migratory phenotype. Mechanistically, we identified RBM11 as a representative splicing factor that is upregulated in tumors after therapy and shed in extracellular vesicles upon induction of apoptosis. Once internalized in recipient cells, exogenous RBM11 switches splicing of MDM4 and Cyclin D1 toward the expression of more oncogenic isoforms. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.